drugset / Trial / NCT00819403

Simvastatin With or Without Ezetimibe and Atherothrombotic Biomarker Assessment

NCT00819403

RandomizedCrossoverTriple-blindTreatment

Summary

To determine whether the combination of ezetimibe and simvastatin improves biomarkers of atherothrombosis compared to simvastatin alone in patients with the metabolic syndrome.

Timeline

Start
2009-01
Primary completion
2011-11
Completion
2011-11

Drugs

EvaluationDrugModalityDoseRoute
Comparator Ezetimibe Unknown 10 mg
Comparator Simvastatin Small molecule 40 mg

Indications